Drug intelligence / Profile preview

HBL-4

Development stage: Preclinical
Lead developer: MedKoo Biosciences
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
Administration: Not Applicable

Overview

HBL-4 is a **PROTAC (proteolysis targeting chimera)** designed to target **BRD (bromodomain-containing proteins)**. This small molecule has the chemical formula C41H49N9O9 and a molecular weight of 811.90. PROTACs work by recruiting target proteins to E3 ubiquitin ligases, leading to ubiquitination and subsequent proteasomal degradation of the target protein. HBL-4 is intended for use in research and is not approved for human or veterinary use[1].

Targets

BRD (Bromodomain-containing protein family)

Beyond the preview

Go deeper on HBL-4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HBL-4.

Explore the full profile